Wegovy

News

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk.

News

Novo Nordisk has had its NDA for an oral formulation of Wegovy accepted by the FDA. It would be the first obesity-targeted GLP-1 in pill form.

News

Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound.

News

Novo Nordisk has enlisted the aid of major telehealth companies as it tries to dominate the self-pay market for obesity drugs in the US.

News

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White House.

Market Access

Recent advancements in weight-loss interventions are transforming the healthcare landscape and presenting new M&A opportunities